Posted by Michael Wonder on 11 Nov 2022
Akari Therapeutics granted FDA rare paediatric disease designation of nomacopan for the treatment of paediatric HSCT-TMA
10 November 2022 - Akari Therapeutics today announced the US FDA has granted the rare paediatric disease designation to nomacopan for the treatment of paediatric haematopoietic stem cell transplant-related thrombotic microangiopathy.
The rare paediatric disease designation is an important addition to the orphan drug and fast track designations previously granted by the FDA for nomacopan in paediatric haematopoietic stem cell transplant-related thrombotic microangiopathy.
